Ironwood Pharmaceuticals (IRWD) said late Wednesday it is reducing its workforce by about 50% because of "ongoing pricing pressures."
The company said the reduction will be primarily driven by "the elimination of Ironwood's field force," with expected restructuring charges of about $20 million to $25 million to be incurred mainly in H1.
The company said the reorganization is expected to yield annual operating expense savings of about $55 million to $60 million and add $40 million to $45 million to annual profits.
The company also said it is winding down a phase 2 exploratory study of apraglutide as a potential treatment of Graft-versus-Host Disease.
The company promoted Greg Martini to chief financial officer and appointed Tammi Gaskins chief commercial officer.
Ironwood expects 2025 revenue of $260 million to $290 million. Analysts polled by FactSet expect $312 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.